Pricing guide

Texas Life Sciences Insurance Cost Guide

This guide covers premium ranges across the Texas life-sciences segment — pharmaceutical and medical device contract manufacturers (CDMOs), contract research organizations (CROs), medical device manufacturers, biotech and clinical-stage drug companies, compounding pharmacies, 503B outsourcing facilities, and clinical and diagnostic labs. Premium varies materially by sub-vertical, regulatory class, and risk profile. Use the figures below as a starting framework, not a quote.

Coverage type → premium range

Annual premium, mid-market Texas CDMO ($5M-$50M revenue). Specific quotes depend on submission.

Commercial General Liability (with Products & Completed Operations)

Base CGL with products and completed ops, $1M / $2M / $5M tower for a typical mid-market pharma CDMO.

Standalone primary CGL; $5M products typically achieved with umbrella stack.

$12K – $35K/ year

Products Liability (Standalone $5M tower)

Products & Completed Operations limit at $5M aggregate, often via $1M primary + $4M umbrella.

Sterile injectables, biologics, and oncology can run materially higher ($80K+).

$30K – $90K/ year

Recall Extension

First-party recall expense coverage, $1M-$5M typical limits.

Premium scales with production volume and distribution scope.

$4K – $25K/ year

Cargo / Warehouseman's Liability

Coverage for sponsor-owned raw materials and finished goods at your facility plus in-transit.

Limit set to typical inventory on premises plus a buffer.

$5K – $18K/ year

Cyber Liability

$3M-$5M limits typical for pharma CDMOs handling sponsor-confidential data and 21 CFR Part 11 systems.

PHI volume is the dominant cost driver — diagnostics and personalized therapy push premiums up.

$8K – $30K/ year

Professional Liability / E&O

For CDMOs offering analytical, regulatory, or formulation services beyond pure manufacturing.

Optional for pure-manufacturing CDMOs; required for hybrid CRO/CDMO operations.

$6K – $25K/ year

Excess / Umbrella

$5M-$10M umbrella sitting over CGL and employers liability.

Required to satisfy $5M+ products requirements unless primary is written at higher limits.

$8K – $40K/ year

Cost drivers

Annual revenue
Most carriers price as a function of revenue band — $5M, $10M, $25M, $50M, $100M tiers are common breakpoints.
Product type
Oral solid dose and topicals price lowest. Sterile injectables, biologics, oncology, controlled substances, gene therapy step up substantially.
Sponsor MSA aggregate requirements
Per-location or per-project aggregate endorsements add 5-15% to the relevant lines.
Cleanroom certifications
ISO 5/6/7/8 classification affects underwriting; higher classification is generally cheaper to insure.
Sponsor mix and concentration
Single-sponsor concentration > 40% of revenue often triggers concentration-of-risk pricing on cyber and BI.
Claims and FDA history
Open Warning Letters, recent recalls, or active Consent Decrees materially change renewal pricing or restrict capacity.

Sample programs

Anonymized examples of total annual program cost for representative CDMO operations.

Oral solid dose CDMO · DFW

$15M-$25M

$55K – $120K / year

$5M products tower, $3M cyber, recall, cargo, $5M umbrella. Single-site, two anchor sponsors.

Sterile injectable CDMO · Houston

$30M-$60M

$180K – $350K / year

$10M products tower, $5M cyber, recall, cargo, $5M umbrella. Multi-site, four sponsors. Higher products premium reflects sterile injectable risk.

Hybrid CDMO/CRO · Austin

$10M-$20M

$75K – $160K / year

$5M products, $3M cyber, $3M E&O, recall, cargo. Hybrid manufacturing + analytical services — required E&O on top of products.

Specific to your sponsor MSA

Run the Decoder against your actual sponsor language for a clause-by-clause cost picture.

Run the MSA Decoder

Pricing questions

Common questions about CDMO insurance cost

How much does CDMO insurance cost in Texas?

A typical Texas CDMO program in the $5M-$50M revenue range runs $55,000 to $200,000 per year for full pharma-grade coverage. The largest cost drivers are the products manufactured (sterile injectables and biologics cost materially more than oral solid dose), sponsor MSA limit requirements, and recall extension. Specific quotes depend on submission.

How much products liability does a CDMO need?

Most pharmaceutical and medical device sponsor MSAs require $5M products and completed operations as a floor. Higher requirements ($10M, occasionally $20M) appear in oncology, biologics, sterile injectable, and controlled-substance manufacturing. Run the MSA Decoder to see specific requirements for your sponsor.

Why is pharma-grade insurance more expensive than general manufacturing?

Three reasons: (1) products and completed operations exposure is harder to underwrite for pharma due to bodily-injury severity, (2) GMP and regulatory compliance creates audit and Warning Letter exposure carriers price for, and (3) the dedicated life-sciences markets with appetite for the segment charge a specialty premium over general manufacturing carriers.

Can I reduce my premium without losing MSA compliance?

Sometimes. The most effective levers are (a) per-location aggregate endorsements rather than higher base limits, (b) tighter sponsor confidentiality programs to reduce cyber exposure, (c) consolidating umbrella across all GL/products lines rather than buying separate excess on each, and (d) clean GMP / FDA inspection history that supports renewal credits.

What is the difference between a $5M and $10M aggregate?

In dollar terms, going from $5M to $10M typically adds $15K to $40K in annual premium for a mid-market CDMO. In coverage terms, $10M is required when the sponsor MSA explicitly mandates it (oncology, biologics, controlled substances) or when aggregate exhaustion across multiple sponsor MSAs is a real concern. The Decoder flags whether your specific sponsor MSA needs $10M.

Are recall costs covered under products liability?

No. Products liability covers third-party bodily injury and property damage from your product. Recall is a first-party expense — your costs to recall, retrieve, and dispose of the product — and requires a separate recall extension. Most pharma sponsor MSAs require both, sized at $1M-$5M.

Compounding pharmacies & 503B

Sterile compounding and outsourcing-facility premium ranges.

503A sterile compounders typically run $40K–$75K total program premium for a multi-suite operation with druggist PL, products, GL, property with sterile peril, cyber, crime, and umbrella. 503B outsourcing facilities scale higher — $80K–$250K — driven by FDA-registered manufacturer property exposures, larger products towers, and recall extensions written for cGMP environments.

GLP-1 compounding adds material premium uncertainty post-March 2026 FDA enforcement. Markets willing to write the exposure are limited and pricing is moving; expect underwriting to require volume caps, BMI screens, prescriber supervision documentation, and telehealth platform controls.

Medical device manufacturers

GPO supplier programs and products tower pricing.

Mid-market FDA Class II device manufacturers typically run $50K–$200K total program premium, driven by the products tower scaling to GPO requirements ($10M-$25M for higher-risk implantables) and cyber for connected devices. Class III devices and surgical implants push higher with PMA-aligned recall extensions and FDA MDR liability.

Premium drivers: revenue, product mix (implantables vs. diagnostic equipment vs. wearables), GPO contract count and aggressiveness, FDA recall history, and connected-device cyber exposure.

Biotech & clinical-stage drug companies

D&O and clinical trial liability pricing benchmarks.

Pre-clinical biotech runs $25K–$75K total program (D&O $15K-$40K, CGL/EPLI/cyber $10K-$25K). Phase 1-2 clinical-stage adds clinical trial liability ($15K-$50K depending on subject count and indication) plus expanded D&O with public-company language. Phase 3 and commercial-launch-ready programs scale to $250K-$1M+, dominated by D&O at $100K-$500K with $1M-$5M retentions.

Securities-class-action history is the largest single underwriting factor. Companies with concentrated pipelines, recent regulatory pauses, or short-seller activity face materially harder D&O markets.